Clinical Trial

The Effect of Echinacea (Immulant ®) in the Treatment of CRYPTOSPORIDIOSIS in Immunocompromised Children

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 5, 2026 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
This study aims to: 1. To evaluate the effectiveness of Immulant ® addition to standard treatment in reducing clinical symptoms of Cryptosporidiosis in immunocompromised children. 2. To measure the changes in parasite count in stool samples after treatment with Immulant ®. 3. To assess the safety and tolerability of Immulant ® in children participating in the study.
Trial Details
NCT Number NCT07388615
Lead Sponsor Al-Azhar University
Conditions Cryptosporidium Infection
Enrollment 60 participants
Start Date 2026-01-18
Primary Completion 2026-06 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2026-02-05